Despite decades of research, our understanding of the processes controlling late-stage atherosclerotic plaque stability remains poor. A prevailing hypothesis is that reducing inflammation may improve advanced plaque stability, as recently tested in the Canakinumab Anti-inflammatory Thrombosis Outcome Study (CANTOS) trial, in which post-myocardial infarction subjects were treated with an IL-1β antibody. Here, we performed intervention studies in which smooth muscle cell (SMC) lineagetracing Apoe -/mice with advanced atherosclerosis were treated with anti-IL-1β or IgG control antibodies. Surprisingly, we found that IL-1β antibody treatment between 18 and 26 weeks of Western diet feeding induced a marked reduction in SMC and collagen content, but increased macrophage numbers in the fibrous cap. Moreover, although IL-1β antibody treatment had no effect on lesion size, it completely inhibited beneficial outward remodeling. We also found that SMC-specific knockout of Il1r1 (encoding IL-1 receptor type 1) resulted in smaller lesions nearly devoid of SMCs and lacking a fibrous cap, whereas macrophage-selective loss of IL-1R1 had no effect on lesion size or composition. Taken together, these results show that IL-1β has multiple beneficial effects in late-stage murine atherosclerosis, including promotion of outward remodeling and formation and maintenance of an SMC-and collagen-rich fibrous cap.
D espite decades of research, little is known about the factors and mechanisms controlling the stability of late-stage atherosclerotic lesions 1 . However, human pathology studies suggest that the cellular composition of plaques-specifically of the fibrous cap, a structure that separates the thrombogenic lesion contents from the blood-is a critical predictor of plaque rupture. Plaques with a higher ratio of CD68 + cells relative to ACTA2 + cells, presumed to be macrophages and SMCs, respectively, are more prone to rupture [2] [3] [4] . However, the markers used for identification of the lesion cells (for example, ACTA2 and CD68) are not specific for SMCs or macrophages during atherosclerosis, which raises questions as to the origin of these cells and, more importantly, their functional roles in late-stage complications 5 . Importantly, results of recent SMC lineage-tracing studies from our laboratory 6, 7 and others 8, 9 have demonstrated that SMCs play a much larger role during atherosclerosis than previously appreciated. Specifically, we found that > 80% of SMC-derived cells within advanced lesions lack expression of the conventional SMC marker, ACTA2, and nearly 50% express markers of alternative cell types such as macrophages or mesenchymal stem cells 7, 8 . Interestingly, we found that SMCs can have beneficial or detrimental roles in lesion pathogenesis depending on the nature of their phenotypic transitions. For example, KLF4-dependent transitions, including formation of SMC-derived macrophage-marker + foam cells 7 , exacerbate lesion pathogenesis, whereas OCT4-dependent transitions 6 are necessary for the formation of an SMC-rich, protective fibrous cap. Taken together, these results highlight the importance of identifying strategies that promote beneficial, while preventing detrimental, changes in SMC phenotype and function.
A dominant hypothesis in atherosclerosis is that excessive inflammation or failed inflammation resolution is a major contributor to plaque development and late-stage lesion destabilization 10, 11 . Indeed, there is extensive evidence that inflammation promotes atherosclerosis development (reviewed in reference 12 ), including that global knockout of IL-1β 13 or the gene encoding its functional receptor, IL-1 receptor type 1 (Il1r1) 14 , reduces plaque formation, whereas knockout of the endogenous IL-1 receptor 1 antagonist gene (IL1ra) increases plaque development 15 . In addition, administration of the IL-1β -neutralizing antibody (mouse gevokizumab) throughout Western diet feeding in Apoe -/mice decreased overall plaque burden 16 . These studies strongly implicate IL-1β in promoting plaque development. However, there are currently no preclinical studies showing a benefit of inhibiting IL-1β after the establishment of advanced atherosclerosis. Importantly, the recently completed CANTOS trial tested 3 doses (50, 150, and 300 mg) of an anti-IL-1β antibody, canakinumab, administered quarterly to a very high-risk cohort of post-myocardial infarction subjects with reduced low-density lipoprotein cholesterol but increased high-sensitivity C-reactive protein (hsCRP) levels 17, 18 . Initial results of the CANTOS trial showed no benefit in all-cause Articles Nature MediciNe or cardiovascular mortality at any of the drug doses, but met its primary end point of a reduction in a composite index of non-fatal myocardial infarction, non-fatal stroke, and cardiovascular disease only with the 150 mg dose 19 . However, a subsequent CANTOS report showed a 31% reduction in cardiovascular mortality and allcause mortality in the subset of CANTOS subjects who achieved on-treatment hsCRP levels of < 2.0 mg l −120 . However, this patient cohort represents a small fraction of all patients at risk for cardiovascular disease, and there was no direct evidence that IL-1β inhibition enhanced plaque stability. As such, there is a critical need for mechanistic studies to define how inhibition of IL-1β impacts late-stage lesion pathogenesis. 
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Despite a clear role for IL-1 signaling in atherosclerosis development, previous studies have not clearly defined the principle cell types that respond to IL-1β in atherosclerosis. However, two bone marrow chimeric studies have suggested that IL1 primarily acts on nonhematopoietic cell types during atherosclerosis development 21, 22 . Specifically, transplantation of Il1r1 -/bone marrow into wild-type mice had no effect on lesion formation, whereas transplantation of wild-type bone marrow into Il1r1 -/mice resulted in significantly smaller lesions, suggesting that non-hematopoietic cell types mediate IL-1 signaling during atherosclerosis development. Interestingly, Sui and co-workers 9 showed that SMC-selective deletion of the Iκ B kinase IKK-β , which is required for activation of NFκ B, attenuated lesion development, suggesting a critical role for inflammatory signaling in SMCs. The latter results are also consistent with several in vitro studies identifying IL-1β as a potent regulator of SMC migration and proliferation [23] [24] [25] . However, the direct role of IL-1 signaling in SMCs during atherosclerosis pathogenesis is unknown.
In the current study, we tested the hypothesis that IL-1β inhibition induces beneficial changes in the setting of established atherosclerosis. To this end, we treated SMC lineage-tracing Apoe -/mice with a mouse anti-IL-1β antibody between 18 and 26 or 18 and 21 weeks of Western diet feeding. Contrary to our expectations, late-stage IL1β antibody treatment resulted in multiple detrimental changes, including (1) a rapid remodeling of the fibrous cap, characterized by reduced collagen and SMC content but a large increase in macrophages, and (2) no decrease in lesion size but impaired beneficial outward vessel remodeling leading to reduced lumen diameter. Equally surprising, we found that macrophage-selective knockout of the Il1r1 in Apoe -/mice had no discernible effect, but SMC-specific Il1r1 knockout resulted in lesions highly enriched in macrophages relative to SMCs with failure to form an SMC-rich fibrous cap. As such, these studies reveal an unanticipated beneficial role for IL-1β in the formation and maintenance of a protective SMC/collagen-rich fibrous cap during late-stage atherosclerosis. 
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Results
IL-1β neutralization decreased systemic and local inflammation in advanced atherosclerotic lesions.
Although several studies have previously demonstrated that global disruption of IL-1 signaling inhibits lesion development in Apoe -/mice 13-15 , they may not predict the effects of acute inhibition of IL-1β on established atherosclerotic lesions 26 . To study the impact of IL-1β inhibition on advanced lesions, we performed intervention studies in which we administered an anti-IL-1β antibody (mouse monoclonal antibody; 10 mg kg −1 ) or an isotype-matched IgG LGALS3 Ki67
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LGALS3 Articles Nature MediciNe control (10 mg kg −1 ) for 8 weeks to SMC lineage-tracing Apoe -/mice (Apoe -/-Myh11 Cre ER T2 R26R-YFP) that had been fed a Western diet for 18 weeks ( Fig. 1a and Supplementary Fig. 1a ).
Mice were fed the same Western diet during the atherosclerosis lesion development (8-26 weeks of age) and the IL-1β antibody treatment (26-34 weeks of age). SMC lineage-tracing Apoe -/mice 
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were treated with tamoxifen between 6 and 8 weeks of age, before initiation of Western diet feeding, to permanently label mature MYH11 + SMCs and to track their fate and that of their progeny during development and progression of atherosclerosis as well as during intervention with an anti-IL1β antibody. We have previously shown that these mice exhibit high efficiency (> 95%) of SMC-specific labelling by YFP expression when treated with tamoxifen from 6 to 8 weeks of age 7, 27 . Treatment with the IL-1β antibody potently reduced systemic inflammation, including a 50% decrease in the plasma concentration of Serum Amyloid-A ( Fig. 1b ) and similar reductions in IL-1β levels in plasma and liver ( Fig. 1c) . Notably, liver and plasma IL-1α concentrations were unchanged ( Supplementary Fig. 1b ). IL-1β neutralization did not alter body weight or plasma cholesterol and triglyceride levels ( Supplementary Fig. 1c-e ). To unbiasedly assess the effects of IL-1β neutralization in atherosclerotic lesions, we performed RNA sequencing (RNA-seq) analyses on brachiocephalic artery (BCA) and aortic arch regions from SMC lineage-tracing Apoe -/mice after 8 weeks of treatment with the IL-1β antibody or the IgG control. Analysis of transcript expression showed that IL-1β antibody treatment induced a global reduction in inflammation within lesions as illustrated by the large number of downregulated inflammatory pathways ( Fig. 1d and Supplementary Table 1 ).
Interestingly, there was also downregulation of cell lineage and cell cycle regulatory pathways. The most upregulated pathways in IL-1β antibody-treated mice included carbohydrate and energy metabolism ( Fig. 1d ). To determine whether the antibody had direct neutralizing properties within the lesion, we assessed the IL-1β antibody penetration into atherosclerotic lesions using Rag1-deficient mice which do not produce mature T cells and B cells 28 . The use of Rag1 -/mice allows for rigorous detection of the mouse monoclonal IL-1β -neutralizing antibody without interference of endogenous antibodies. The IL-1β antibody was detected at higher levels than the IgG control in atherosclerotic lesions from Rag1 -/-Apoe -/mice fed for 26 weeks with a Western diet, suggesting a direct effect of the neutralizing antibody within atherosclerotic lesions ( Supplementary Fig. 1f ). Secondly, the local inhibition of the IL-1 signaling pathway was confirmed by immunostaining showing a significant decrease in phospho-IRAK and IL-6 in SMC lineage-tracing Apoe -/mice treated with the IL-1β antibody as compared to controls ( Fig. 1e ). Taken together, these results demonstrate that the IL-1β antibody treatment regimen was effective at inhibiting the IL-1 signaling pathway, resulting in a decrease in both systemic and local plaque inflammation.
Neutralization of IL-1β induced multiple unexpected changes in late-stage atherosclerotic lesions.
Despite effective inhibition of inflammation, analysis of atherosclerotic plaque burden and BCA plaque morphometry showed multiple unexpected results believed to be detrimental for plaque pathogenesis. IL-1β neutralization had no impact on aortic plaque burden ( Fig. 2a ,b) or BCA lesion size (Fig. 2c,d and Supplementary Fig. 2 ), but completely inhibited the beneficial outward vessel remodeling that normally occurs during plaque expansion (Fig. 2c,d and Supplementary  Fig. 2 ). Consequently, IL-1β antibody-treated mice had significantly reduced lumen area ( Fig. 2d ). Even more surprising, IL-1β antibody treatment resulted in a profound reduction in YFP + SMC and an increase in YFP − LGALS3 + macrophages ( Fig. 2e and Supplementary  Fig. 3 ). This change in cell composition was particularly evident in the fibrous cap area (defined as the 30-µ m-thick subluminal area within the lesion which is typically enriched in YFP + and ACTA2 + cells, as previously reported 7 ) ( Fig. 2f,g and Supplementary  Fig. 3b ,c). The increase in the LGALS3 + population within the fibrous cap area was driven by an increase in the number of non-SMC-derived YFP − LGALS3 + macrophages (bone marrow-derived or resident macrophages), whereas the number of SMC-derived macrophage-like cells (YFP + LGALS3 + ) was unchanged ( Fig. 2g ). However, the proportion of YFP + LGALS3 + cells normalized to the total YFP + SMC population was significantly increased with IL-1β antibody treatment ( Fig. 2h ), suggesting that YFP + LGALS3 + cellsin contrast to YFP + and YFP + ACTA2 + populations-might be resistant to loss or clearance following IL-1β neutralization. The reduction in SMC content was associated with an overall decrease in the ACTA2 + fibrous cap thickness ( Fig. 2i ). Moreover, inhibition of IL-1β also induced a significant reduction in collagen content within the fibrous cap area, a key index of plaque stability ( Supplementary Fig. 4b,c ). This reduction in collagen content within the fibrous cap area could be a direct consequence of the loss of SMCs, described in previous studies as a major producer of collagen within the lesion 29 , but could also be due to IL-1β -induced upregulation of collagenases. There was no difference in the expression of MMP3 and MMP9 ( Supplementary  Fig. 4d ,e), two collagenases known to be regulated by IL-1β 30 . However, further studies of collagenase activity would be required to ascertain the mechanisms by which inhibition of IL-1β leads to collagen loss (that is, decrease in production and/or increase in degradation). Interestingly, these changes to the fibrous cap area occurred despite having no effect on the necrotic core area or intraplaque hemorrhage ( Supplementary Fig. 4f-h ), suggesting that there has not been effective lesion regression or complete resolution of lesion inflammation. Moreover, there was no difference in the lesion calcification ( Supplementary Fig. 5a ,b) or in the proportion of YFP + SMCs expressing RUNX2, a master regulator of SMC osteogenic transitions ( Supplementary Fig. 5c,d) .
The main features of the IL-1β inhibition described above were also observed when mice were treated with a lower dose of the IL-1β -neutralizing antibody (1 mg kg −1 ) for 8 weeks ( Supplementary  Fig. 6a ). Treatment with the IL-1β antibody at 1 mg kg −1 induced a significant impairment of beneficial outward remodeling ( Supplementary Fig. 6b ,c) and reduced YFP + SMCs and increased LGALS3 + macrophages within the fibrous cap ( Supplementary  Fig. 6d,e ). Taken together, the preceding results unexpectedly show that IL-1β is critical for maintaining an SMC/collagen-rich, macrophage-poor fibrous cap area.
Macrophage accumulation was driven by local proliferation rather than increased monocyte recruitment. To better understand the mechanisms responsible for the enrichment of macrophages and loss of SMCs following 8 weeks of IL-1β inhibition, we investigated the effects of 3 weeks of treatment. Apoe -/-Myh11 Cre ER T2 R26R-YFP mice were treated with the IL-1β antibody (10 mg kg −1 ) or the IgG control between 18 and 21 weeks of Western diet feeding (Fig. 3a) . Remarkably, just 3 weeks of IL-1β antibody treatment resulted in profound changes to the cellular composition of the fibrous cap, characterized by an increase in the proportion of LGALS3 + cells and a reduction in YFP + SMCs (Fig. 3b,c) . This shift reflected a net increase in the number of LGALS3 + cells within the fibrous cap of mice treated with the IL-1β antibody (Fig. 3d ). The LGALS3 + population was composed predominantly of YFP − LGALS3 + cells, whereas the SMC-derived YFP + LGALS3 + population was unchanged (Fig. 3e ). Furthermore, the increase in macrophages occurred predominantly in the fibrous cap area (Fig. 3b) . These data not only support a critical role for IL-1β in maintaining the integrity of the fibrous cap but also reveal that the fibrous cap area, as a structure, is much more plastic than previously appreciated.
To determine whether the increase in the LGALS3 + population was driven by increased bone marrow-derived monocyte recruitment into the plaque, we quantified monocyte influx using a fluorescent latex bead trafficking assay 31, 32 . In brief, Cy3-labeled beads were injected intravenously into Apoe -/-Myh11 Cre ER T2 R26R-YFP mice one week before initiation of antibody treatment ( Fig. 4a and Articles Nature MediciNe Supplementary Fig. 7a ). Mice injected with beads received either the IL-1β -neutralizing antibody or IgG control antibody for 3 weeks. Flow cytometry analysis of blood collected 24 h after the bead injection demonstrated efficient labeling of circulating monocytes consistent with previous reports ( Supplementary Fig. 7b,c) [31] [32] [33] . Importantly, there were no changes in blood cell populations after the bead and antibody treatment ( Supplementary Fig. 7d ). BCA plaques from IL-1β antibody-and IgG control-treated mice showed no differences in bead accumulation (Fig. 4b,c ). However, IL-1β antibody-treated mice exhibited a marked decrease in the ratio of beads to macrophages (Fig. 4c ), suggesting that the macrophage accumulation induced by IL-1β inhibition was not due to an increase in newly recruited monocytes.
To determine whether the accumulation of macrophages was driven by proliferation, we performed immunostaining for Ki67 on mice treated with 3 weeks of IL-1β antibody or IgG control (Fig. 4d ). Although the overall fraction of proliferating cells was not significantly changed (Fig. 4e) , treatment with the IL-1β antibody profoundly changed which cell types underwent proliferation in the fibrous cap. Specifically, there was a marked reduction in YFP + SMC proliferation and an increase in macrophage (YFP − LGALS3 + ) proliferation ( Fig. 4e,f ). However, there was no change in the proliferation of YFP + LGALS3 + cells, indicating that the exacerbation of LGALS3 + proliferation did not include SMC-derived macrophage-like cells ( Fig. 4f ). Of note, IL-1β inhibition did not induce changes in endothelial cell proliferation ( Supplementary Fig. 8 ). We also assessed the proportion of YFP + and LGALS3 + cells undergoing apoptosis in these same samples. TUNEL (Fig. 4g,h) and cleaved caspase-3 ( Supplementary Fig. 9 ) analyses showed no differences in apoptosis of SMCs or macrophages in IL-1β antibody-treated mice as compared to controls. Taken together, these data show that inhibition of IL-1β profoundly impacts the cell composition within advanced atherosclerotic plaques primarily by inhibiting SMC proliferation and promoting proliferation of macrophages within lesions.
IL-1 signaling is required for SMC investment into lesions and the fibrous cap.
The preceding observations demonstrate that inhibition of IL-1β in mice with advanced lesions resulted in a dramatic reduction in SMCs and increase in macrophages within the fibrous cap. However, it is unclear whether these changes were mediated via direct loss of IL-1 signaling in SMCs, macrophages, or other cell types within the lesions.
Thus, to ascertain the role of IL-1 signaling in SMCs in atherosclerosis development, we generated mice with tamoxifen-inducible SMC-specific Il1r1 knockout and simultaneous SMC lineage tracing by crossing Il1r1 fl/fl mice 34 with Apoe -/-Myh11 Cre ER T2 R26R-YFP mice ( Supplementary Fig. 10a ). The resulting Apoe -/-Myh11 Cre ER T2 R26R-YFP Il1r1 fl/fl and littermate control Il1r1 WT/WT mice were treated with a series of tamoxifen injections from 6 to 8 weeks of age to induce simultaneous expression of a YFP lineage-tracing gene, and excision of exon 5 of the Il1r1 gene exclusively in SMCs 7,27 (designated below as Il1r1 SMC Δ/Δ or Il1r1 SMC WT/WT ) before being fed a Western diet for 18 weeks ( Supplementary  Fig. 10b ). We observed high-efficiency recombination of Il1r1 in SMC-rich tissues including aorta, carotid, and lung in tamoxifentreated Il1r1 SMC fl/fl mice ( Supplementary Fig. 10c ). Recombination of the Il1r1 locus was associated with corresponding reductions in IL-1R1 protein expression based on immunohistochemical staining of carotid medial SMCs in Il1r1 SMC Δ/Δ mice with an anti-IL-1R1 antibody ( Supplementary Fig. 10d ). There were no significant differences in body weight or serum cholesterol and triglyceride levels ( Supplementary Fig. 10e,f) . However, remarkably, we observed a > 60% reduction in BCA plaque size in Il1r1 SMC Δ/Δ mice as compared to Il1r1 SMC WT/WT mice (Fig. 5a,b) , as well as a marked reduction in collagen content (Fig. 5c,d ), but no difference in intraplaque hemorrhage (Fig. 5e,f) . Of major interest, the lesions in the Il1r1 SMC Δ/Δ mice were almost entirely devoid of SMCs (YFP + ) and ACTA2 + cells, but significantly enriched in YFP − LGALS3 + cells ( Fig. 5g-i) . This was particularly evident in the fibrous cap area which exhibited a > 80% reduction in YFP + area and a 70% decrease in ACTA2 + area. In addition, fibrous cap areas from Il1r1 SMC Δ/Δ mice had a 2.8-fold increase in LGALS3 + area (Fig. 5i ).
We also tested the effect of macrophage-selective Il1r1 -/on atherosclerosis development using Apoe -/-LysM Cre R26R-YFP Il1r1 fl/fl and Apoe -/-LysM Cre R26R-YFP Il1r1 WT/WT littermate control mice fed Western diet for 18 weeks ( Supplementary Fig. 11a,b) . Importantly, this LysM Cre gene targeting results in efficient gene targeting of monocytes, mature macrophages, and granulocytes 35 . LysM Cre-driven knockout of IL1R1 induced a complete inhibition of the IL-1 signaling pathway as demonstrated by the lack of IRAK phosphorylation in LGALS3 + YFP + cells within atherosclerotic lesions of Il1r1 macrophages Δ/Δ ( Supplementary Fig. 11e ). In contrast to the profound effects of SMC-specific Il1r1 deletion, there was no significant effect of losing IL-1R1 in LysM-expressing cells on vessel size, lesion size, or the frequency of YFP + , LGALS3 + , or ACTA2 + cells ( Supplementary Fig. 12 ). Taken together, these cell-specific Il1r1 knockout studies provide compelling evidence that IL-1 signaling in SMCs, rather than myeloid cells, plays a critical role during atherosclerosis development. Moreover, results suggest that the reductions in indices of plaque stability observed in our IL-1β neutralization experiments, including the marked loss of SMCs and collagen, as well as increases in macrophages within the fibrous cap, are due, at least in part, to disrupted IL-1 signaling in SMCs.
IL-1β neutralization increased IL-4 levels and promoted macrophage M2 polarization.
To determine potential mechanisms altering the cellular composition of the fibrous cap following IL-1β antibody treatment, we performed a cytokine and chemokine array on BCA tissue extracts from mice treated for 8 weeks with either IL-1β or control antibody (Fig. 6a ). Interestingly, there was a twofold increase in IL-4 protein level in BCA lesions from the IL-1β antibody-treated mice. Of interest, IL-4 has been shown to inhibit SMCs 36,37 but promote resident macrophage proliferation 38, 39 , consistent with our in vivo Ki67 staining data (Fig. 4 ). IL-4 has also been identified as a key cytokine involved in M2 polarization of macrophages in vitro 40, 41 . To better understand the impact of IL-1β neutralization on macrophage phenotype, we performed staining for classic M1 (iNOS) and M2 (Arg1) markers. Although there are considerable limitations to the M1/M2 paradigm, confocal analyses of these markers permit studies of individual macrophages within the fibrous cap and their possible functions. Consistent with increased IL-4, there was a decrease in the number of LGALS3 + iNOS + , but a large increase in Arg1 + -expressing macrophages within the fibrous cap area (Fig. 6b,c) . These results suggest that IL-1β neutralization induces an anti-inflammatory phenotype in resident macrophages within the fibrous cap that is mediated, at least in part, by increased IL-4.
Discussion
Our present study provides compelling evidence of a critical role for IL-1 signaling during late-stage atherosclerosis. However, contrary to our expectations, IL-1 signaling appeared to play multiple beneficial roles that were lost by either IL-1β neutralization or SMCspecific knockout of Il1r1. Indeed, although lesions from SMCspecific Il1r1 knockout Apoe -/mice were smaller, they exhibited a number of changes believed to be detrimental, including failure to form a protective ACTA2 + fibrous cap, reduced collagen content, and increased macrophage content. Likewise, IL-1β antibody treatment of SMC lineage-tracing Apoe -/mice with advanced atherosclerosis decreased multiple plaque stability indices, including a 40% decrease in SMC content, > 50% decrease in ACTA2 + coverage, 30% reduction in collagen content, and 50% increase in macrophage Articles Nature MediciNe (M2) content within the fibrous cap. Taken together, these observations have several important implications. First, our results indicate an unexpected role for IL-1β in regulating fibrous cap formation in advanced lesions and suggest that excessive inhibition of inflammation could have detrimental effects. Tabas and co-workers have long emphasized the importance of improving inflammation resolution, rather than suppression, as a key therapeutic approach for stabilizing lesions 10, 42, 43 . Second, the fibrous cap is far more plastic than anticipated, a finding that, if true in humans, may have important implications for atherosclerotic disease management and the development of more effective therapeutic approaches. Third, our results highlight the need for increased emphasis on intervention rather than prevention models in preclinical atherosclerosis studies seeking to identify novel therapies for treating advanced atherosclerosis 26 . The importance of this concept is made particularly clear when comparing the previous prevention study that treated Apoe -/mice from the beginning of Western diet feeding with an IL-1β antibody and showed reduced plaque formation 16 , with our intervention study that showed no improvement on the same measurement and changes consistent with plaque destabilization. Therefore, one cannot assume that pharmacologic agents that are effective in preventing fatty streak formation in young animals will necessarily have beneficial effects in the setting of established atherosclerosis.
One of the most striking observations following IL-1β neutralization in advanced lesions was the loss of SMCs but increase in macrophages within the fibrous cap. Our data suggest that this is driven in part by reduced SMC proliferation, which is consistent with in vitro studies showing that IL-1β induces SMC proliferation 24, 25 . However, it is also possible that global IL-1β inhibition may be associated with impaired migration and/or homing of SMCs and/or macrophages into the fibrous cap due to changes in the production of or sensitivity to guidance cues. Consistent with this possibility, Moore and coworkers 44, 45 have identified several macrophage chemo-attractant and chemo-repulsive proteins whose production by SMCs could be regulated by IL-1β . However, the accumulation of macrophages was driven by local proliferation of macrophages rather than increased monocyte recruitment from the blood. These observations are consistent with studies by Swirski and co-workers 46 showing that local proliferation of macrophages, rather than monocyte trafficking, regulates macrophage expansion in established lesions.
Of interest, we present correlative evidence suggesting that increased expression of IL-4 may contribute to reduced proliferation of SMCs while simultaneously stimulating proliferation of local macrophages and their M2 polarization. Consistent with this possibility, IL-4 has previously been shown to induce these changes in cultured SMCs and macrophages, respectively 36, 38, 39 . Although M2 macrophages have been shown to play a beneficial role in atherosclerosis pathogenesis, it remains to be determined whether an influx of M2 or M2-like macrophages into the fibrous cap would be beneficial or detrimental. However, our results suggest that this may be detrimental due to: (1) the loss of SMCs and collagen; and (2) the increase in M2 macrophages which occurs despite failure to resolve the necrotic core, reduce the extent of intraplaque hemorrhage or calcification, or clear plaque cholesterol crystals 47 . That is, global IL-1β suppression may be inducing a false sense of inflammation resolution that results in premature dissolution of the SMC/ collagen-rich fibrous cap. Consistent with this possibility, our SMC Il1r1 knockout studies indicate that IL-1 signaling is required for investment of these cells into the fibrous cap (Fig. 5 ). In addition, IL-1β potently induces multiple processes in cultured SMCs that are likely to be important in fibrous cap formation and maintenance, including proliferation 24 , migration 30 , and collagen synthesis 29 .
A critical question is to determine to what extent, if any, our IL-1β antibody intervention studies in mice translate to patients, including those in the CANTOS trial 19 . The results of CANTOS represent a major advance for the cardiovascular field for several reasons. First, they 19, 20 provide the most direct evidence to date validating the inflammation hypothesis of atherosclerosis in man. Second, they are the first to achieve a reduction in cardiovascular risk in high-risk subjects with advanced atherosclerotic disease via a therapy independent of lipid lowering (see our editorial 48 and others 49, 50 ). However, it is critical to appreciate that: (1) CANTOS met its primary end point only at the intermediate of three doses tested; and (2) an overall benefit on all-cause and cardiovascular mortality was restricted to the subset of CANTOS subjects who achieved ontreatment hsCRP levels of < 2.0 mg l −1 (ref. 20 ). These latter results are quite exciting in that they indicate that canakinumab may be an appropriate therapy for this subset of very high-risk post-myocardial infarction subjects, but would seem to be at odds with our findings that IL-1β antibody treatment of Apoe -/mice with advanced lesions resulted in rapid loss of SMCs and collagen within the fibrous cap ( Figs. 2 and 3) .
However, there are major limitations in directly comparing our mouse intervention studies with the outcome of the CANTOS trial. First, there are inherent differences between humans and mice, including differences in disease time-course and treatment periods, as well as fundamental immune system differences, and lack of genetic diversity in mice. In addition, > 80% of CANTOS subjects had a percutaneous coronary intervention or coronary bypass; > 90% were taking antithrombotic, lipid-lowering, and/or anti-ischemic agents; and > 79% were on inhibitors of the renin-angiotensin system. Second, it is possible that we are modeling fundamentally different mechanisms than those operative in CANTOS subjects, including effects of a prior myocardial infarction and associated infarct remodeling that was not a component of our experimental design. Third, there are several studies reporting improved glycemic control and insulin sensitivity with inhibition of IL-1 signaling 9,51,52 . However, a recent report showed that, within the CANTOS trial patient cohort, canakinumab had similar effects on occurrence of cardiovascular events among subjects with diabetes or prediabetes, but the treatment itself did not reduce diabetes incidence 53 . Fourth, our mice are severely hypercholesterolemic, whereas the CANTOS subjects had relatively well-managed cholesterol levels (for example, low-density lipoprotein cholesterol < 83 μ g ml −1 ). We feel that this may be an absolutely critical determinant of the effects of global IL-1β suppression in the context of advanced atherosclerosis. Indeed, in light of the marked increase in cardiovascular deaths resulting from widespread use of the anti-inflammatory COX2 inhibitor rofecoxib (Vioxx) 54 , a major challenge moving forward will be to determine to what extent canakinumab or other broadly acting anti-inflammatory agents should be extended to lower-risk patients. Specifically, it will be critical to determine strategies to identify subsets of patients that will exhibit the most benefit from these therapies, and perhaps more importantly to determine whether there are patients that may be more susceptible to the adverse effects. In support of this hypothesis, two clinical studies are consistent with our findings and suggest that inhibition of IL-1 signaling may unexpectedly increase the risk for some cardiovascular events. First, the MRC-ILA Heart Study was a phase IIb, double-blinded, randomized, placebo-controlled study of anakinra, a recombinant IL-1 receptor antagonist (IL-1ra), administered for two weeks to subjects following a non-ST elevation myocardial infarction 55 . Although not powered to measure longterm outcomes, the study showed that anakinra treatment increased major adverse cardiovascular events, including myocardial infarction, at one year by greater than fourfold. Second, studies by the IL-1 Genetics Consortium 56 investigated two common variants located upstream of the IL-1ra locus known to increase its expression. This retrospective study of 746,171 subjects showed that increased levels of IL-1ra are correlated with reduced hsCRP and IL-6, consistent with reduced systemic inflammation, but with an allele-dependent increase in coronary artery disease. As such, we believe that the greatest value of our late-stage atherosclerosis intervention studies Articles Nature MediciNe in mice is to generate hypotheses, which might then be tested in man to better understand the mechanistic and physiological aspects of IL-1β inhibition. In addition, armed with a greater understanding of the basic vascular biology, the field can identify alternative (or combinatorial) anti-inflammatory therapeutic targets that are both effective and safe for treating a broader and lower risk cohort of human subjects.
Methods
Methods, including statements of data availability and any associated accession codes and references, are available at https://doi. org/10.1038/s41591-018-0124-5.
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Methods Study design. The objectives of these studies were to determine the effects of IL-1β inhibition on established atherosclerotic lesions and to identify the consequences of IL-1β neutralization and cell-specific loss of IL-1 signaling. To achieve this, we performed an intervention study in which atheroprone Apoe -/mice were treated with a mouse monoclonal anti-IL-1β antibody provided by Novartis following 18 weeks of Western diet. At this time point, BCAs consistently develop advanced atherosclerotic lesions with common features of end-stage human lesions, including large necrotic cores, collagen-rich fibrous caps, and intraplaque hemorrhage. The dose of the antibody and the duration of the treatment were prospectively selected based on the pharmacokinetic properties of the antibody. We utilized the well-characterized SMC lineage-tracing Apoe -/-Myh11 Cre ER T2 R26R YFP 7, 27, 57 mice to rigorously lineage trace SMCs and perform qualitative and quantitative assessment of their presence, location, and phenotypic characteristics. Apoe -/-Myh11 Cre ER T2 R26R YFP mice were crossed to Il1r1 floxed mice (fl/fl) to generate tamoxifen-inducible SMC-specific lineage-tracing and Il1r1 knockout mice. We utilized Il1r1 wt/wt and Il1r1 fl/fl littermates to ensure that the IL-1R1deficient and control animals were genetically identical with exception of the Il1r1 locus. All mice were on a C57Bl/6 background and had been backcrossed at least eight generations. Although it would be ideal to study IL-1β neutralization in both males and females, the Myh11 Cre ER T2 transgene is located on the Y chromosome, preventing us from using females in this study. A power analysis with 95% power and α = 0.05 indicated that a sample size of at least 6 mice per group was required for morphometry and immunofluorescence analysis and a minimum of 3 mice per group for the bead assay. We routinely exceeded the minimal number of mice required for each experiment as indicated in the figure legends. All data were included and outliers, if any, were not excluded. Only mice with a plasma cholesterol level < 500 g dl −1 and thus not considered hypercholesterolemic were excluded from analyses. Animals, diet, and treatment. Animal protocols were approved by the University of Virginia Animal Care and Use Committee. The Apoe -/-Myh11 Cre ER T2 R26R-YFP mice used in the intervention study have been described in previous studies 6, 7, 27 . These mice were crossed with Il1r1 fl/fl mice that were generated, characterized 34 , and provided by Dr. Emmanuel Pinteaux. Male Apoe -/-Myh11 Cre ER T2 Il1r1 fl/wt R26R-YFP and Apoe -/-Il1r1 fl/wt R26R-YFP female mice were bred to generate Apoe -/-Myh11Cre ER T2 Il1r1 fl/fl or wt/wt R26R-YFP littermate experimental mice. Male Apoe -/-LysM Cre Il1r1 fl/fl or wt/wt R26R-YFP littermates were generated in a similar fashion. All mice were carefully genotyped by PCR as previously described 27, 34, 57 . In Myh11 Cre ER T2 mice, Cre recombinase was activated with a series of 10 tamoxifen injections (1 mg d −1 per mouse; Sigma Aldrich, T-5648) over a 2-week period. One week after the tamoxifen treatment, mice were fed a high-fat Western-type diet, containing 21% milk fat and 0.15% cholesterol (Harlan Teklad, TD.88137) for 18, 21, or 26 weeks. Before beginning Western diet, mice were fed a standard chow diet purchased from Harlan Teklad (TD.7012). For our intervention studies, Apoe -/-Myh11 Cre ER T2 R26R-YFP mice received intraperitoneal injections of anti-IL-1β antibody or IgG control (provided by Novartis) when they reached 18 weeks of Western diet feeding for either 3 or 8 weeks while remaining on Western diet. Anti-IL-1β antibody or IgG control were injected weekly at the concentrations 10 mg kg −1 or 1 mg kg −1 . To ensure advanced lesions, the Rag1 -/-Apoe -/mice were fed 26 weeks of Western diet before starting a series of 8 weekly injections with the IL-1β antibody or the IgG control (10 mg kg −1 ). Mice were euthanized by CO 2 asphyxiation after overnight fasting, and peripheral blood was collected by cardiac puncture. Whole blood and plasma were used respectively for circulating blood cell count and cholesterol and triglyceride analyses, which were performed by the University of Virginia Clinical Pathology Laboratory. Immediately after CO 2 asphyxiation, mouse carcasses were perfused via the left ventricle with 5 ml PBS, 10 ml 4% paraformaldehyde, and 5 ml PBS. BCAs were then dissected, processed, and embedded in paraffin.
Plaque burden analysis by Sudan IV staining. Aortas from Apoe -/-Myh11
Cre ER T2 R26R-YFP mice treated with anti-IL-1β antibody or IgG control for 8 weeks were dissected from the aortic arch to the iliac bifurcation and subjected to en face Sudan IV staining (n = 6 per group). In brief, after carefully removing the peri-adventitial fat, aortas were dehydrated in 70% ethanol for 5 min and incubated in Sudan IV solution for 6 min, which was prepared as follows: 1 g Sudan IV (Sigma Aldrich, S4261) was diluted in 100 ml 70% ethanol and 100 ml 100% acetone. Finally, aortas were differentiated in 80% ethanol for 3 min and stored in PBS at 4 °C.
Immunohistochemistry and atherosclerotic plaque morphometry.
Paraformaldehyde-fixed, paraffin-embedded BCAs were serially cut in 10-µ mthick sections from the aortic arch to the bifurcation of the right subclavian artery. For morphometric analysis, we performed modified Russell-Movat staining on three locations along the BCA at 150 µ m, 450 µ m, and 750 µ m from the aortic arch, as previously described 6, 7 . The lumen, lesion, and necrotic core areas, as well as the external elastic lamina (vessel area), the internal elastic lamina, the medial area, and the medial thickness, were measured on digitized images of the Movat staining using Image Pro Plus Software 7.0 (Media Cybernetics). Picrosirius red and Von Kossa staining were performed to assess collagen content and calcification, respectively. Immunohistochemistry was performed with antibodies against IRAK phospho-T209 (4 µ g ml −1 , Abcam), IL-6 (4 µ g ml −1 , Bioss Antibodies), IL1R1 (4 µ g ml −1 , Bioss Antibodies), MMP3 (7.7 µ g ml −1 , ab53015, Abcam), MMP9 (2 µ g ml −1 , ab38898, Abcam), and TER-119 (1 µ g ml −1 , Santa-Cruz Biotechnology). Staining for immunohistochemistry was visualized by 3,3'-diaminobenzidine (Acros Organics). Integrated optical densitometry analysis of 3,3'-diaminobenzidine staining was performed using Image Pro Plus Software 7.0 (Media Cybernetics).
Immunofluorescent staining. BCA sections were deparaffinized and rehydrated in xylene and ethanol series. After antigen retrieval (H-3300, Vector Laboratories), sections were blocked with fish skin gelatin PBS (6 g l −1 ) containing 10% horse serum for 1 h at room temperature. Slides were incubated with the following antibodies: mouse monoclonal SM α -actin-FITC (ACTA2) (4.4 μ g ml −1 , clone 1A4, Sigma Aldrich), goat polyclonal anti-GFP (4 µ g ml −1 , ab6673, Abcam) for detection of YFP, LGALS3 (2 µ g ml −1 , Cedarlane CL8942AP), RUNX2 (1.374 µ g ml −1 , ab192256, Abcam), Ki67 (4 µ g ml −1 , ab15580, Abcam), PECAM-1 (1 µ g ml −1 , Santa Cruz), IRAK phosphor-T209 (4 µ g ml −1 , Abcam), iNOS (0.52 µ g ml −1 , ab15323, Abcam), and Arg1 (9.2 µ g ml −1 , GTX109242, GeneTex). The secondary antibodies were donkey anti-rat conjugated to Alexa 555 (5 μ g ml −1 , Abcam), donkey anti-rat conjugated to Alexa 647 (5 μ g ml −1 , Abcam), donkey anti-goat conjugated to Alexa 555 (5 μ g ml −1 , Invitrogen), and donkey anti-goat conjugated to Alexa 647 (4 μ g ml −1 , Invitrogen). Apoptosis was assessed by TUNEL (CF488A, Biotium) and cleaved caspase-3 staining (0.84 μ g ml −1 , ab9661, Cell Signaling Technology). IL-1β antibody was detected using a donkey anti-mouse IgG2a-Alexa 488 antibody. DAPI (0.05 mg ml −1 , D3571, ThermoFisher) was used as a nuclear counterstain and slides were mounted using Prolong Gold Antifade (Invitrogen).
Monocyte trafficking-bead assays. Apoe -/-Myh11 Cre ER T2 R26R-YFP mice fed Western Diet (Harlan Teklad, TD.88137) for 17 weeks received an injection of Fluoresbrite Polychromic Red 1.0 μ m beads (2.5% solids-latex; Polysciences, Inc., no. 18660). Beads were diluted in sterile PBS (1:4 dilution) and 250 µ l diluted beads were injected retro-orbitally. Twenty-four hours after the injection, blood was collected by tail bleeding and selective uptake of the beads by circulating Ly6C low monocytes was assessed by flow cytometry (see 'Flow cytometry' section). At 5-7 d after the bead injection, we started the anti-IL-1β antibody or IgG control regimen (10 mg kg −1 ) for a duration of 3 weeks as described above. At the end of the antibody treatment, mice were euthanized by asphyxiation. Mice were perfusion fixed with periodate-lysine-paraformaldehyde. Each BCA was harvested, postfixed in periodate-lysine-paraformaldehyde, and incubated in a gradient of sucrose solutions before being embedded in optimal cutting temperature compound. Serial frozen 10-µ m-thick sections were used to perform immunofluorescent staining for LGALS3 (Cedarlane, CL8942AP) and DAPI for nuclear staining. Endogenous fluorescent signal of Fluoresbrite Polychromic Red beads was directly detectable.
Imaging. Movat, IL1R1, MMP3, Ter119, and Sudan IV staining of BCAs was imaged using a Zeiss Axioskope2 microscope equipped with an AxioCamMR3 camera. Image acquisition was performed with AxioVision40 version 4.6.3.0 software (Carl Zeiss Imaging Solution). Digitized images were analyzed with Image Pro Plus Software 7.0 (Media Cybernetics). Immunofluorescent staining was imaged using either a Zeiss LSM700 or a Nikon A1 confocal microscope to acquire a series of 8 z-stack images at 1-μ m intervals. Zen 2009 Light Edition Software (Zeiss) or NIS-Element 5.02 Software (Nikon) were used for analysis of each z-stack image and single-cell counting was performed for phenotyping and quantifying the cell population within the 30-µ m-thick layer proximal to the lumen (fibrous cap area). Assessment of YFP + , ACTA2 + , and LGALS3 + areas (normalized to lesion or fibrous cap area) was performed using maximal intensity projection images and the analysis was done using Image Pro Plus Software 7.0 (Media Cybernetics). Maximal intensity projection of representative images was used to generate the representative images included in the figures, and Adobe Photoshop was used to process and format images.
RNA-seq and data analysis. RNA sequencing and analysis. Total RNA was isolated using Trizol (Invitrogen) from the BCA and aortic arch region of Apoe -/-Myh11 Cre ER T2 R26R-YFP mice fed a high-fat Western diet for 26 weeks and treated with the anti-IL1β antibody (n = 4) or with the IgG control antibody (n = 4) for the last 8 weeks of high-fat Western diet feeding (18-26 weeks). The RNA library was prepared according to Illumina RNA Seq library kit instructions with ribosomal RNA reduction and the deep sequencing was performed by the HudsonAlpha Institute for Biotechnology. Quality control and quantification of RNA and library were performed using an Agilent 2100 Bioanalyzer and a Kapa Library Quantification Kit (Kapa Biosystems), according to the manufacturer's protocol. Libraries were sequenced with the Illumina HiSeq2000 (2 × 100 bp).
Sequence analysis of RNA reads. One hundred-nucleotide paired-end reads were mapped to the mm9 reference genome using STAR software version 2.4 58 . A table of gene counts/quantification was generated using FeatureCounts in the Subread package 59 . We used the DESeq2 Bioconductor R package 60 A power analysis with 95% power and α=0.05 indicated that a sample size of at least 6 mice per group was required for morphometry and immunofluorescence analysis and a minimum of 3 mice per group for the bead assay. We routinely exceeded the minimal number of mice required for each experiment as indicated in the figure legends.
Data exclusions
Describe any data exclusions. All data were included and outliers, if any, were not excluded. Only mice with a plasma cholesterol level <500 g/dL and thus not considered hypercholesterolemic were excluded from analyses.
Replication
Describe whether the experimental findings were reliably reproduced.
Replications were successful.
Randomization
Describe how samples/organisms/participants were allocated into experimental groups.
We randomly distributed litter mates in either the IL-1b antibody treated group or the IgG control treated group.
For IL1R1 KO studies, we utilized Il1r1wt/wt and Il1r1fl/fl littermates to ensure that the IL-1R1 deficient and control animals were genetically identical with exception to the Il1r1 locus. All mice were on a C57Bl/6 background and had been backcrossed for at least 8 generations.
Although it would be ideal to study IL-1β neutralization in both males and females, the location of the Myh11 Cre ERT2 transgene on the Y chromosome prevents us from using females in this study.
Blinding
Describe whether the investigators were blinded to group allocation during data collection and/or analysis.
The investigators were blinded regarding treatment or genotype during experimental procedures or data acquisition.
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Statistical parameters
For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or in the Methods section if additional space is needed).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same sample was measured repeatedly A statement indicating how many times each experiment was replicated
The statistical test(s) used and whether they are one-or two-sided (note: only common tests should be described solely by name; more complex techniques should be described in the Methods section)
A description of any assumptions or corrections, such as an adjustment for multiple comparisons
The test results (e.g. P values) given as exact values whenever possible and with confidence intervals noted A clear description of statistics including central tendency (e.g. median, mean) and variation (e.g. standard deviation, interquartile range)
Clearly defined error bars
See the web collection on statistics for biologists for further resources and guidance.
Software
Policy information about availability of computer code
Describe the software used to analyze the data in this study.
Digitized images were analyzed with Image Pro Plus Software 7.0 (Media Cybernetics). Immunofluorescent staining was imaged using a Zeiss LSM700 confocal microscope. Zen 2009 Light Edition Software (Zeiss) was used to acquire a series of eight z-stack images at 1um intervals. Zen 2009 Light Edition Software (Zeiss) was used for analysis of each z-stack image and single-cell counting was performed for phenotyping and quantifying the cell population comprised within the 30um thick layer proximal to the lumen (i.e., fibrous cap area). FlowJo Version 10 software was used for flow cytometry analyses. For RNAseq analysis, base calls was performed using CASAVA; reads were aligned to the mm9 genome using STAR version 3.0; aligned reads were counted against genes from the UCSC mm9 annotation using the featureCounts from the SubRead package; DESeq2 was used to normalize (normalized for library size using the DESeq2 median ration normalization procedure), and to perform differential gene expression; pathway analysis was performed using GAGE.
For manuscripts utilizing custom algorithms or software that are central to the paper but not yet described in the published literature, software must be made available to editors and reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). Nature Methods guidance for providing algorithms and software for publication provides further information on this topic.
Materials and reagents
Policy information about availability of materials
Materials availability
Indicate whether there are restrictions on availability of unique materials or if these materials are only available for distribution by a for-profit company.
There is restriction in availability of the IL-1b neutralizing antibody provided by Novartis. Other reagents are available.
nature research | life sciences reporting summary Animal protocols were approved by the University of Virginia Animal Care and Use Committee. The Apoe-/-Myh11 Cre ERT2 R26R-YFP mice used in the intervention study have been described in previous studies. For the intervention studies, mice are injected with tamoxifen between 6 and 8 weeks of age and fed a Western Diet between 8 and 29 or 34 weeks of age. Mice are euthanized at 29 or 34 weeks of age. These mice were crossed with Il1r1fl/fl mice that were generated, characterized, and provided by Dr. Emmanuel Pinteaux. Male Apoe-/-Myh11 Cre ERT2 Il1r1fl/wt R26R-YFP and Apoe-/-Il1r1fl/wt R26R-YFP female mice were bred to generate Apoe-/-Myh11Cre ERT2 Il1r1fl/fl or wt/wt R26R-YFP littermate experimental mice. Apoe-/-LysM Cre Il1r1fl/fl or wt/wt R26R-YFP littermates were generated in a similar fashion. All mice were carefully genotyped by PCR as previously described. Apoe-/-Myh11Cre ERT2 Il1r1fl/fl and Apoe-/-LysM Cre Il1r1fl/fl mice are fed a Western Diet for 18 weeks and euthanized at 26 weeks of age.
All mice were on a C57Bl/6 background and had been backcrossed for at least 8 generations. Only males were used in these studies due to the location of the Myh11 Cre ERT2 transgene on the Y chromosome preventing using females.
Policy information about studies involving human research participants
Description of human research participants
Describe the covariate-relevant population characteristics of the human research participants.
This study did not involve human research participants.
